A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

Launched by MINGSIGHT PHARMACEUTICALS, INC · May 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called MS-553, which is a specific type of medication designed to help patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) whose disease has not responded to other treatments or has come back after previous treatment. The study is currently not recruiting participants yet, but it aims to include adults aged 18 and older who have a confirmed diagnosis of CLL or SLL and need treatment based on specific guidelines.

If you join this trial, you can expect to receive the MS-553 medication and be monitored closely by medical professionals to see how well it works and if there are any side effects. However, people with certain conditions, such as active autoimmune diseases or other types of lymphoma, may not be eligible to participate. This study is important as it may provide new options for patients who have limited treatment choices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older.
• 2. Diagnosis of CLL or SLL:
• • 1. History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and
• • 2. Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-
• Exclusion Criteria:
• • 1. Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.
• • 2. Active and uncontrolled autoimmune cytopenia(s).